Last years’ geopolitical changes have been amending the pharmaceutical industry and market, making governments and businesses review their supply chain, business partners’ countries of origin and other vital aspects to ensure business continuation and provision of comprehensive medical services. Building partnerships and strengthening links with like-minded countries in the EU in trade, investments and innovations have become pivotal.
Recognising Italy’s excellence in life science we are determined with the assistance of ASSORAM to embark on establishing long-term partnerships where Latvia can share its know-how built over many decades and is renowned internationally.
Agenda
The event will take place on October 09th from 4 to 5.30 PM – stand Olpha Booth n. 16B50 pad. n. 16
Only associates
- 4:00 – Registration
- 4:15 – Remarks by H.E. Elita Gavele, Ambassador of Latvia to Italy
- 4:20 – Remarks by Pierluigi Petrone, ASSORAM President and Prof. Alfredo Sassi, ASSORAM Vice President
- 4:25 – Remarks by Guntis Rubins, Head of Representative Office in Italy of Latvian Investment and Development Agency
- 4:30 – Life sciences and technologies in Latvia – Juris Bundulis, Chairman of the Board of Olpha JSC
- 4:40 – Investment opportunities and environment – Ieva Trumane, Senior Investment Advisor, LIAA Investment Department, Presentation about the
- 5:30 –Networking
- In 2023 the life science industry turnover was EUR 1,1 billion of which EUR 900,7 m was export;
- The Latvian Institute of Organic Synthesis is the leading Baltic regional centre for drug discovery;
- Local pharma companies can offer full cycle production from APIs (Active Pharmaceutical Ingredients) till FDFs (Final dosages forms), as well as contract manufacturing and development cooperation;
- In 2024, it is projected that the revenue in the pharmaceuticals market in Latvia will reach EUR 304.6 m with an expected annual growth rate 3.63% between 2024-2029;
- The largest market within the pharmaceuticals market industry is Oncology Drugs, which is expected to have a market volume of EUR 48,27m in 2024;
- Latvia’s pharmaceutical market is witnessing a surge in demand for personalized medicine and innovative treatments.
